Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Targeting multiple immune mechanisms may overcome therapy resistance and further improve cancer immunotherapy for humans. The authors of a new article published in Acta Pharmaceutica Sinica B describe ...

Cancer immunotherapy has transformed modern oncology by harnessing the body’s own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...

Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS ...

Givastomig is designed to simultaneously target CLDN18.2 and 4-1BB. CLDN18.2 is a tight junction protein that is typically ...

(A) Presence of PD-1, its ligands PD-L1 and PD-L2, and the phosphatases SHP-1, SHP-2, and SHP-2-like (SHP-2L) in representative jawed vertebrates, including sharks, ray-finned fish, amphibians, and ...